



Sean Bagshaw <bagshaw@ualberta.ca>

AKI-EPI 2 Newsletter – July 2026 Update

1 message

Hoste Eric <Eric.Hoste@uzgent.be>

Fri, Jul 10, 2026 at 3:55 AM

To: "antoine.schneider@chuv.ch" <antoine.schneider@chuv.ch>, Cristiani Isabelle <Isabelle.Cristiani@chuv.ch>, Vermeiren Daisy <Daisy.Vermeiren@uzgent.be>, "dawno@ualberta.ca" <dawno@ualberta.ca>

Dear AKI-EPI 2 Investigators,

On behalf of the AKI-EPI 2 Executive Committee, we would like to thank all participating centres for their tremendous efforts and continued commitment to this international collaboration.

1. Recruitment update


We are delighted to report that, as of 10 July 2026, the study has reached:

- **10,554** included patients
- **159** participating centres
- **35** countries
- 16 countries are in the final stages of the regulatory process

This milestone reflects the remarkable engagement of investigators worldwide and highlights the truly global nature of the AKI-EPI 2 project. Thank you to all centres that have contributed patients and data so far.



10,554 patients, 159 centers, 35 countries



2. AKI-EPI 2 study protocol published in BMJ Open

We are pleased to announce the publication of the AKI-EPI 2 study protocol in BMJ Open. The publication describes the rationale, design and objectives of the study and represents an important milestone for the project. [\[bmjopen.bmj.com\]](https://bmjopen.bmj.com)

Reference: Schneider AG, Vandenberghe W, Bellomo R, et al. *Acute kidney injury-epidemiology in intensive care unit patients 2: study protocol for a prospective international multicentre cohort study*. BMJ Open. 2026;16:e119063.

Link: <https://bmjopen.bmj.com/content/16/7/e119063.full>

Please feel free to share the publication within your institutions and professional networks.

3. Study timeline and next steps

To ensure timely completion of the project, we would like to remind all centres that **patient inclusion will end on 31 December 2026**.

For centres that are still completing regulatory or administrative requirements, we kindly ask you to make every effort to **accelerate the start-up process** so that patient recruitment can begin as soon as possible.

In parallel, we ask all participating centres to ensure that collected data are entered into the REDCap eCRF on a regular basis. Timely data entry is essential for maintaining data quality, monitoring study progress and preparing the final analyses.

Key actions

- ✓ Continue recruiting eligible patients
- ✓ Centres not yet active: expedite local start-up and regulatory processes
- ✓ Enter all collected data into the REDCap eCRF as soon as possible
- ✓ Verify completeness and accuracy of existing records

A sincere thank you

We would like to express our heartfelt thanks to all investigators, research coordinators, study nurses, data managers and ICU teams involved in AKI-EPI 2. Conducting a large international study alongside the demands of daily clinical care is a significant commitment, and we are truly grateful for the time, energy and dedication you continue to invest in this project.

Thanks to your efforts, AKI-EPI 2 has already become one of the largest prospective international studies of acute kidney injury in critically ill patients, with more than 10,500 patients enrolled across 159 centres in 35 countries. This achievement is a direct reflection of your commitment and collaboration.

We are excited about what we can accomplish together during the remainder of the study and look forward to sharing further milestones and results with you in the coming months.

With best regards,

Eric Hoste and Antoine Schneider
On behalf of the AKI-EPI 2 Executive Committee
Ghent University Hospital, Belgium

P.S. Please feel free to share this newsletter with your entire local AKI-EPI 2 team.

E-maildisclaimer: <https://www.uzgent.be/e-maildisclaimer>